OncRef

Clinical Trial: NCT03769129

Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

Status:

RECRUITING

Phase:

Not Applicable

Lead Sponsor:Second Affiliated Hospital of Guangzhou Medical University
Information Provided By:Second Affiliated Hospital of Guangzhou Medical University
Last Update Posted:2024-06-25

Study Overview

Brief Summary

This is a prospective, randomized, single clinical study designed to evaluate its safety and efficacy by using Microwave Ablation combine with Pembrolizumab in patients with Stage ⅢB-Ⅳ Non-small Cell Lung.Cancer (NSCLC) who failed with first-line therapy.

Official Title

A Prospective,Single Center, Randomized Control,Phase III Clinical Study for Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Patients With Stage ⅢB-Ⅳ NSCLC Who Failed With First-line Therapy

Conditions

Non Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Pembrolizumab
  • Procedure: microwave ablation

Other Study ID Numbers

  • ZZWMAICI-005

Start Date (Actual)

2018-11-01

Primary Completion Date (Estimated)

2026-11-01

Study Completion Date (Estimated)

2029-11-01

Enrollment (Estimated)

100

Study Type

Interventional

Phase

Not Applicable